^
    Apply
    A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors (NCT04984668)
    Phase 1/2
    Suzhou Kintor Pharmaceutical Inc,
    Recruiting
    Last update posted :
    02/09/2024
    Initiation :
    11/02/2021
    Primary completion :
    04/01/2025
    Completion :
    12/01/2025
    PD-L1
    |
    PD-L1 expression
    |
    erfonrilimab (KN046) • ascrinvacumab (GT90001)
    PF-03446962 in Relapsed or Refractory Urothelial Cancer (NCT01620970)
    Phase 2
    Fondazione IRCCS Istituto Nazionale dei Tumori,...
    Completed
    Last update posted :
    05/14/2021
    Initiation :
    03/01/2012
    Primary completion :
    06/01/2013
    Completion :
    06/01/2013
    EGFR • HER-2 • PTEN • KIT • IL6 • FLT1
    |
    ascrinvacumab (GT90001)